

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/052955 A1

(51) International Patent Classification⁷: A23L 1/30, 1/221, A61K 45/06

(21) International Application Number: PCT/EP01/11736

(22) International Filing Date: 10 October 2001 (10.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2000A002854
29 December 2000 (29.12.2000) IT

(71) Applicant (for all designated States except US): HUNZA DI PISTOLESI ELVIRA E C. S.A.S. [IT/IT]; Via Gavirate, 7, I-20148 Milano (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): PISTOLESI, ELvira [IT/IT]; Via Gavirate, 7, I-20148 Milano (IT).

(74) Agents: MINOJA, Fabrizio et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY

WO 02/052955 A1

(54) Title: NUTRITIONAL AND THERAPEUTICAL PREPARATIONS HAVING ANTIOXIDANT ACTIVITY

(57) Abstract: Pharmaceutical and dietary compositions, as well as to functional foodstuffs useful as coadjuvants for both treating and preventing aging processes and related conditions: atherosclerosis, hypertension, diabetes, tumors, obesity and overweight, hypertriglyceridemia, hypercholesterolemia, aging of the skin, alopecia, panniculopathy (cellulite), osteoporosis, cerebral aging (Alzheimer, Parkinson, senile dementia, etc.) and loss of memory, stress, depression, menopausal syndromes, benign prostate hypertrophy, etc.. Said compositions comprise: a) a lipidic mixture rich in polyunsaturated acids and vitamins, in combination with at least two components selected from; b) one or more terpenes selected from monoterpenes and/or sesquiterpenes; c) 1-piperoylpiperidine in the pure form and/or extracts or purified fractions enriched in black pepper containing it; d) one or more polycosanols and/or polycosanolic acids.

NUTRITIONAL AND THERAPEUTICAL PREPARATIONS HAVING ANTIOXIDANT ACTIVITY

The present invention relates to pharmaceutical and dietary compositions, as well as to functional foodstuffs useful as coadjuvants for both preventing and treating aging processes and related conditions: atherosclerosis, hypertension, diabetes, tumors, obesity and overweight, hypertriglyceridemia, hypercholesterolemia, aging of the skin, alopecia, panniculitis (cellulite), osteoporosis, cerebral aging (Alzheimer, Parkinson, senile dementia, etc.) and loss of memory, stress, depression, menopausal syndromes, benign prostate hypertrophy, and the like.

Said compositions comprise:

- a) a lipidic mixture rich in polyunsaturated fatty acids, preferably docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), conjugated linoleic acids (CLA) and γ -linolenic acid, and antioxidant vitamins, in combination with at least two of the following components:
- b) one or more terpenes, selected from monoterpenes and/or sesquiterpenes, triterpenes, lactonic terpenes, but preferably monoterpenes or sesquiterpenes,
- c) 1-piperoylpiperidine (in pure form and/or purified extracts or fractions containing it enriched in black pepper) and/or capsaicin and analogues thereof, preferably 1-piperoylpiperidine,
- d) one or more polycosanols and/or polycosanolic acids.

The lipidic mixture can contain the polyunsaturated fatty acids in the form of tri-, di- and monoglycerids, phospholipid esters, free acids or alkali or alkaline-earth metal salts, salts with amino acids (arginine, lysine, methionine, cysteine, and the like) or salts with nitrogen bases such as ethanolamine, mono- and dimethylethanolamine, choline, and the like, or as ethyl esters. Preferred sources of these unsaturated acids

are oils from sea animals (from cod, mackerel, tuna, seal, etc.) and/or oils from different types of seeds (maize, soy-bean, sunflower, colza, wheat germ, borage, "evening primrose", red currant, linseed, perilla, etc.), olive, seaweed, pepper, mushrooms (for example *Mucor javanicus*) oils, lecithins and phospholipids of different nature, etc. with various purity degrees.

The antioxidant vitamins of the lipidic mixture can be selected from one or more of the following compounds:

vitamin E, lipoic acid, vitamin C as such and/or as acyl derivative, vitamin B6 as such and/or as acyl derivative, folic acids, vitamin B12, etc.; water-soluble vitamins (vitamin B6, folic acids, vitamin B12, etc.) are preferably added in the form of complexes with lecithins which promote their dispersion in the lipidic mixture.

Examples of monoterpenes include d-limonene, β -caryophyllene, sabinene, borneol, carveol, carvone, eugenol, eugenol acetate, geraniol, menthol, myrtanol, pinene, β -pinene, thymol, and the like.

Examples of sesquiterpenes include abscisic acid, β -ionone, rodinal, and the like.

Examples of lactonic terpenes include ginkgolides, bilobalides, and the like.

Examples of triterpenes include madecassic acid, asiatic acid, asiaticoside, etc.


Preferred sources of these terpenes are suitably purified fractions of:

A) fruit or vegetable or spices essential oils rich in limonene, thymol, menthol, etc..

and

B) medicinal herbs essential oils (such as *Ginkgo biloba*, *Centella asiatica*, etc..) rich in lactonic terpenes and triterpenes.

1-Piperoylpiperidine, of formula:




can be present as pure compound or it can be contained in black pepper (*piper nigrum*) extracts.

Examples of vegetable extracts containing 1-piperoylpiperidine are extracts in apolar solvents of black pepper fruits which, after evaporation of the solvent, may either be used crude or be further purified by column chromatography or other conventional techniques to obtain highly pure fractions of 1-piperoylpiperidine (above 95%).

10 Capsaicin and its analogues can be present as pure compounds or contained in extracts of red pepper (*capsicum annuum L.*), chili, paprika, etc..

15 Examples of polycosanols (long chain aliphatic alcohols: $C \geq 24$) include octacosanol, triacosanol, tetracosanol and hexacosanol. Preferred sources of these polycosanols are suitably purified wax fractions of maize, wheat, rice, citrus fruits, sugar cane, and the like.

Examples of polycosanolic acids (saturated long chain fatty acids: $C \geq 24$,



20 are octacosanolic acid (montanic acid), triacosanolic, tetracosanolic, hexacosanolic acids, and the like. Preferred sources of these polycosanolic acids are suitably purified wax fractions of maize, wheat, rice, citrus fruits, sugar cane, sea animals fats, and the like. Alternatively, these fatty polycosanolic acids can easily be obtained by chemical oxidation of the alcohol group of the corresponding 25 polycosanols according to conventional oxidation procedures.

The preparation of octacosanolic acid from the corresponding octacosanol (or a mixture of polycosanols containing it) is reported in the following by way of example.

Octacosanol was dissolved in 200 ml of acetic acid, treated with 75 g of chromic acid in acetic acid, and left for 2 hr at 0°C and 1 hr at room temperature. Dilute 5 hydrochloric acid and benzene were added to the mixture and the extract was evaporated under reduced pressure. The residual oil was partitioned between benzene and a solution of 5% sodium hydroxide in water-methanol 2:1. From the benzene layer, 30 g of neutral material was recovered. An oil that separated from the aqueous layer was acidified with hydrochloric acid and treated with benzene, which was evaporated to give 40 g of octacosanolic acid. The methyl ester of the latter was pure 10 by GLC analysis. The product was distilled at 170°C/0.01 mm. This method is a partial modification of the procedure by Steinberg for the preparation phytanic acid from the corresponding phytol (Daniel Steinberg et al., (1966), J. Lipid Res., vol. 7, pp 684 - 690; Effects of dietary phytol and phytanic acid in animals).

15 Polyunsaturated fatty acids [that are preferably rumenic acid and conjugated linoleic acids (CLA): the positional isomers of CLA include Δ-7, Δ-9; Δ-8, Δ-10; Δ-9, Δ-11; Δ-10, Δ-12; Δ-11, Δ-13, and Δ-12, Δ-14 conjugated octadecadienoic acids. Each 20 of the aforementioned positional conjugated diene isomers can occur in the following geometric configurations: cis-, trans-; trans-, cis-; cis-, cis- and trans-, trans-. Rumenic acid is the proposed common name of the predominant CLA isomer: cis-9, trans-11]; γ-linolenic acid; eicosapentaenoic acid and docosahexaenoic acid] are present in the compositions of the invention in amounts ranging from 0.01 to 500 mg, preferably from 5 to 50 mg per kg body weight of the treated subject.

25 Vitamins are present in the compositions of the invention in amounts corresponding to their daily dosage ranges used in humans. Particularly preferred ranges are the following:

- 1) vitamin E : 0.01 to 20 mg, preferably 0.2 to 0.8 mg per kg body weight;
- 2) lipoic acid: 0.01 to 10 mg, preferably 0.2 to 0.8 mg per kg body weight;

- 3) vitamin C: 0.1 to 50 mg, preferably 0.5 to 3.0 mg per kg body weight;
- 4) vitamin B6: 1 to 300 µg, preferably 5 to 50 µg per kg body weight;
- 5) folates: 0.1 to 30 µg, preferably 2 to 6 µg per kg body weight; and
- 6) vitamin B12: 0.001 to 0.3 µg, preferably 0.02 to 0.06 µg per kg body weight.

5 Terpenes are present in amounts ranging from 0.01 to 100 mg, preferably from 0.5 and 10 mg per kg body weight.

1-Piperoylpiperidine is present in amounts ranging from 0.001 to 5 mg, preferably from 0.02 and 0.2 mg per kg body weight.

10 Capsaicin is present in amounts ranging from 0.01 to 100 mg, preferably from 0.1 and 7.5 mg per kg body weight.

Polycosanols and/or polycosanolic acids are present in amounts ranging from 0.01 to 50 mg, preferably from 0.1 to 2 mg per kg body weight.

15 The compositions of the invention can further contain other conventional components, such as oligoelements, mineral salts, bioflavones, extracts of medicinal herbs, phytosterols, amino acids, peptides, etc.

20 The present invention also relates to the procedures for the preparation of the mixtures of one or more active principles either in the form of oily solutions (see examples 1-3), water-dispersible lipoprotein powders (see examples 4 and 5) or of powders water-dispersible liposaccharide powders (see example 6), as well as to the various oral formulations and functional foodstuffs containing the above mentioned active principles. Oily solutions may be used both for the preparation of suitable functional foodstuffs (dressing oils and oily food derivatives such as margarine, butter, mayonnaise, sauces, creams, chocolate, etc.) and for the galenic formulations consisting of hard- or soft- gelatin capsules containing them.

25 The water-dispersible lipoprotein powders are prepared by complexing lipophilic active principles with suitable water-soluble protein excipients such as albumins, delipidized albumins, soy-bean proteins, wheat proteins, caseins, milk serum proteins, gelatins, and the like. The water-dispersible liposaccharidic powders are prepared by

complexing the lipophilic active principles with suitable saccharide excipients such as lactose, starches, cellulose, honey or fractions thereof, chitins and chitosans, pectins, inulins, natural fibers, cyclodextrins, and the like.

Both powders can be used for the preparation of a variety of functional foodstuffs, for example by:

- a) mixing with flours for the preparation of bread, pasta, cracker, biscuits or other bakery products;
- b) addition to fruit juices, soft drinks or other beverages;
- c) addition to milk and derivatives thereof (yogurt, puddings, ricotta, cheese, etc.).

Furthermore, said powders can be used for galenic formulations, such as tablets, sugar-coated pills, sachets, effervescent tablets, chewing gums, etc.

Some examples of procedures for the preparation of both the oily mixtures and the powders of the active principles, as well as of the different possible formulations of the invention, are reported in the following:

Example 1: oily solution of:

- a) 18.3 g of a mixture consisting of 60% of fish oil
(containing 28% of EPA and 18% of DHA),
20% of borage oil (containing 18% of γ -linolenic acid)
and 20% of CLA-enriched maize oil (40%) added with
vitamin E (200 mg), vitamin C palmitate (400 mg),
lipoic acid (100 mg) g 19
+
- b) terpene fractions of essential oils of lemon (70%),
25 thyme (25%), clove (2.5%), and nutmeg (2.5%),
preferably containing d-limonene, sabinene,
 α -pinene, β -pinene, eugenol, thymol, β -caryophyllene g 0.475
+

c) 1-piperoylpiperidine mg 100
+
d) policosanols (80%) and policosanolic acids (20%)
from wax rice g 0.425

5 Mixture a) is heated at 45°-50°C under mild stirring, then slowly added with components b), c) and d) which homogeneously dissolve in a few minutes. The resulting homogeneous oily solution is then cooled at room temperature and stored for further galenic or alimentary uses.

Example 2: oily solution of:

10 a) 18.3 g of cod oil containing 18% of EPA
and 12% of DHA added with vitamin E
(200 mg), vitamin C palmitate (400 mg),
lipoic acid (100 mg) g 19
+
15 b) terpene fractions of essential oils of lemon (70%),
nutmeg (10%), thyme (20%) containing
d-limonene, sabinene, α -pinene, β -pinene, eugenol,
thymol and β -caryophyllene g 0.475
+
20 c) 1-piperoylpiperidine mg 25
+
d) policosanols and/or policosanolic acids from rice wax g 0.5

The oily mixture of the various active principles is prepared as described in Example 1.

25 Example 3: oily solution of:

a) 95.9 g of EPA ethyl ester (50%) + DHA ethyl ester (30%)
+ γ -linolenic acid ethyl ester (20%) added with
vitamin E (600 mg) vitamin C palmitate (1.2 g) and

	lipoic acid (300 mg)	g 98
	+	
b)	terpene fractions of essential oils as in Example 1	g 1
	+	
5	c) 1-piperoylpiperidine as in Example 1	mg 50
	+	
d)	polycosanols and/or polycosanolic acids from sugar cane wax	g 0.9

The oily mixture of the various active principles is prepared as described in
10 Example 1.

Example 4: water-dispersible lipoprotein powders of:

a)	delipidized egg albumin or milk caseins or soy proteins or a mixture thereof)	g 500
	+	
15 b)	terpene fractions of essential oils as in Example 1	g 5
	+	
c)	1-piperoylpiperidine	g 0.05
	+	
20 d)	polycosanols and/or polycosanolic acids from citrus wax	g 5
	+	
e)	vitaminized mixture of fish oil, oil of borage and CLA as in Example 1	g 30

All the components are dissolved under stirring in 2.5 liters of water and mixed
25 for 2/4 minutes in a mechanical blade homogenizer at 20°-25°C; the solution is
subsequently spray-dried to a powder, which is the stabilized water-dispersible
lipoprotein complex of the lipophilic and vitaminic active principles and can be used
as such for the preparation of both pharmaceutical or dietary formulations and various

functional foodstuffs.

Example 5: water-dispersible lipoprotein powders of

5	a) soy proteins	g 250
	+	
	b) 246.95 g of soy lecithin (rich in linoleic and linolenic acids) added with vitamin E (1 g), vitamin C (2 g), vitamin B6 (50 mg), folic acid (100 µg) and vitamin B12 (100)	g 250
	+	
10	c) polycosanols and/or polycosanolic acids from rice wax	g 2,5
	+	
	d) terpene fractions of essential oils as in Example 1	g 5
	+	
15	e) 1-piperoylpiperidine	g 0.05

The powders are prepared as described in Example 5.

Example 6: water-dispersible liposaccharidic powders:

20	a) wheat starch or β -cyclodextrins or pectins or cellulose and vegetable fibers of other species)	g 200
	+	
	b) polycosanols and polycosanolic acids from wheat waxes	g 1.0
	+	
	c) terpene fractions of essential oils as in Example 1	g 1.0
	+	
25	d) 1-piperoylpiperidine	mg 10
	+	
	e) 49.150 g of a mixture of linseed oil (50%) and borage oil (50%) added with vitamin E	

(100 mg) vitamin C palmitate (200 mg), lipoic acid

(50 mg) and vitamin B6 (5 mg)

g 20

The mixture of the different active principles is obtained as described in Example 4.

5 Pharmacological and/or dietetic tests

The pharmacological and/or dietetic characteristics of the compositions of the present invention were experimentally tested on rat and clinically tested on man.

Rats received hypercaloric, hypertriglyceridemizing and hypercholesterolemizing diet. After twenty days of treatment, the effect of the compositions on the following 10 parameters was evaluated:

- 1) lipoperoxides levels in plasma, liver, brain and heart;
- 2) body weight;
- 3) fluidity of the membranes of erythrocyte ghosts and plasma platelets;
- 4) total cholesterol and HDL cholesterol plasma levels;
- 5) total triglycerids plasma levels.

15 80 Male rats, each weighing 150-200 g, were used. The animals were subdivided into 8 groups of 10 animals each:

1st group: control (C); 10 animals (control at time 0) received no treatment, 10 animals received for 20 days standard hypercaloric, hyperlipidemizing and 20 hypercholesterolemizing diet consisting of:

20% casein; 3.5% mixture of oligoelements and mineral salts; 0.1% mixture of vitamins; 0.2% choline ditartrate; 2% cellulose; cholesterol 0.5%; 0.25% sodium cholate; 58.44% saccharose; 10.0% lard and 4.9% olive oil.

25 2nd group: treated with vitaminized fish oil (OP); animals received for 20 days the same diet as the controls, except that 1.9 g of vitaminized fish oil as reported in Example 2 replaced in part a similar amount olive oil (olive oil used: 3.0%).

3rd group A: animals were treated with a polycosanols mixture (octacosanol = 50%) of rice wax (PLC), animals received for 20 days the same diet as the controls,

except that 0.5 g of rice wax polycosanols replaced in part a similar amount of olive oil (olive oil used: 4.4%).

3rd group B: animals were treated with a mixture of polycosanolic acids (PLC ac.) (montanic \approx 50%) obtained by oxidation of the mixture of rice wax polycosanols of 3rd group A; animals received for 20 days the same diet as the controls, except that 0.5 g of rice wax polycosanolic acids replaced in part a similar amount of olive oil (olive oil used: 4.4%).

4th group: animals were treated with a terpene mixture (TRP); animals received for 20 days the same diet as the controls, except that 0.475 g of a terpene mixture as reported in Example 1 replaced in part a similar amount of olive oil (olive oil used: 4.425%).

5 5th group: treated with 1-piperoylpiperidine (P); animals received for 20 days the same diet as the controls, except that 0.025 g of 1-piperoylpiperidine replaced a similar amount of olive oil (olive oil used: 4.875%).

10 15 6th group: treated with a terpene mixture + 1-piperoylpiperidine + vitaminized fish oil (TRP + P + OP); animals received for 20 days the same diet as the controls, except that 1.9 g of vitaminized fish oil + 0.475 g of a terpene mixture + 0.025 g of 1-piperoylpiperidine replaced a similar amount of olive oil (olive oil used: 2.5%).

20 25 7th group: treated with vitaminized fish oil + a mixture of terpenes + 1-piperoylpiperidine + a mixture of polycosanols (50%) and polycosanolic acids (50%) (OP + TRP + P + PCL); animals received for 20 days the same diet as the controls, except that 1.9 g of vitaminized fish oil, 0.475 g of a terpene mixture, 0.025 g of 1-piperoylpiperidine and 0.5 g of polycosanols and polycosanolic acids replaced 2.9 g of olive oil (olive oil used: 2.0 g).

Results are reported in the following tables I, II and III.

Table I - Percent changes of the fluidity of the membrane of erythrocyte ghosts and plasma platelets (expressed as % compared with controls values at time 0) of the rats before and after 20 days of dietary treatment.

	membrane fluidity (erythrocyte ghosts))	membrane fluidity (plasma platelets)
1 st A control rats at time 0	100%	100%
1 st B control rats after 20 day diet	72%	69%
2 nd treated rats (OP)	76%	74%
3 rd A treated rats (PLC)	74%	71%
3 rd B treated rats (Ac. PLC)	82%	81%
4 th treated rats (TRP)	76%	71%
5 th treated rats (P)	73%	70%
6 th treated rats (OP+TRP+P)	90%	91%
7 th treated rats (OP+TRP+P+PLC)	96%	96%

Table II - Lipoperoxides levels [expressed as n mols of malonyldialdehyde (MDA) per gram of tissue or per ml of plasma] in plasma, liver, brain and heart of rats before and after 20 day dietary treatment.

	MDA PLASMA	Percent change vs. controls	MDA LIVER	Percent change vs. controls	MDA BRAIN	Percent change vs. controls	MDA HEART	Percent change compared with controls
1 st A control rats at time 0	2.5 ± 0.5	//	25.5 ± 5.9	//	55 ± 4	//	24 ± 5	//
1 st B control rats after 20 days of diet	5.1 ± 0.6	100%	44.2 ± 8.2	100%	108 ± 6	100%	45 ± 6	100%
2 nd treated rats (OP)	5.0 ± 0.6	-1.9%	45.1 ± 8.2	2%	106 ± 7	-1.8%	44 ± 9	-2.2%
3 rd A treated rats (PLC)	4.8 ± 0.5	-5.8%	43.1 ± 6.5	-2.4%	105 ± 9	-2.8%	42 ± 7	-6.6%
3 rd B treated rats (Ac. PLC)	3.9 ± 0.5	-22.0%	36.2 ± 6.1	-22.1%	95 ± 7	-12.0%	39 ± 7	-13.3%
4 th treated rats (TRP)	4.7 ± 0.4	-7.8%	41.8 ± 8.2	-5.4%	108 ± 7	-0.0%	44 ± 9	-2.2%
5 th treated rats (P)	5.0 ± 0.3	-1.9%	43.5 ± 7.8	-1.5%	107 ± 5	-0.9%	44 ± 7	-2.2%
6 th treated rats (OP+TRP+P)	3.6 ± 0.4	-29.4%	34.7 ± 6.8	-21.4%	81 ± 8	-25.0%	36 ± 8	-20%
7 th treated rats (OP+TRP+P+PLC)	2.9 ± 0.4	-43.1%	29.9 ± 7.1	-32.3%	76 ± 10	-29.6%	32 ± 8	-28.8%

Table III - Change of the body weight and of total cholesterol, HDL cholesterol and triglycerids plasma levels in rats before and after 20 days of diet treatments.

	Total cholesterol (mg dl ⁻¹)	HDL cholesterol (mg dl ⁻¹)	total triglycerids (mg dl ⁻¹)	body weight (g)
1 st A) control rats at time 0	35.6 ± 1.8	26.2 ± 1.4	50.2 ± 7.7	180 ± 12
1 st B) control rats after 20 day diet	126.2 ± 13.5 (100%)	29.4 ± 1.6	82.5 ± 9.5 (100%)	224 ± 19 (100%)
2 nd treated rats (OP)	120.4 ± 12.7 (-4.5%)	28.9 ± 2.8	80.5 ± 6.8 (-2.4%)	221 ± 16 (-1.3%)
3 rd A) treated rats (PLC)	114.3 ± 10.1 (-12.5%)	31.6 ± 3.9	81.4 ± 8.7 (-1.3%)	219 ± 18 (-2.2%)
3 rd B) treated rats (Ac. PLC)	89.2 ± 8.1 (-29.3%)	32.0 ± 4.1	75.2 ± 8.5 (-8.8%)	208 ± 16 (-7.1%)
4 th) treated rats (TRP)	113.9 ± 12.4 (-9.7%)	29.9 ± 2.0	80.4 ± 10.5 (-2.5%)	219 ± 14 (-2.2%)
5 th) treated rats (P)	125.2 ± 12.5 (-0.7%)	29.3 ± 1.5	81.9 ± 8.7 (-0.7%)	223 ± 16 (-0.4%)
6 th) treated rats (OP+TRP+P)	71.7 ± 8.9 (-43.1%)	32.1 ± 3.8	72.5 ± 7.9 (-12.1%)	200 ± 20 (-10.7%)
7 th) treated rats (OP+TRP+P+PLC)	54.8 ± 3.9 (-56.5%)	32.4 ± 4.1	68.7 ± 5.4 (-16.7%)	186 ± 15 (-16.9%)

Membrane fluidity of erythrocyte ghosts and plasma platelets was measured using TMA-DPH as fluorescent probe, according to the method by Caimi F. et al., 1999, Thromb. Haemost., 82 pp. 149.

Malonyldialdehyde was evaluated according to the procedure by K. Yagi et al., 5 1982, in "Lipid Peroxides in Biology and Medicine", Academic Press, New York, pp. 324-340.

The data reported in tables I, II and III evidence that the compositions of the invention are able of promoting, in rats receiving for 20 days a hypercaloric diet and enriched in saturated animal fats and cholesterol, a surprising synergistic effect in:

10 . restoring membrane fluidity of ghosts and platelets;
. improving antioxidant defenses of plasma, liver, brain and heart;
. reducing excessive increase in body weight;
. limiting excessive increase in plasma cholesterol and triglycerid levels.

Said beneficial and therapeutical effects are always significantly higher than the 15 sum of the beneficial effects obtainable by administering separately the single components of the mixture.

The data reported in Tables I, II and III show that mixtures of polycosanolic acids administered alone always promote, in rats receiving for 20 days a hypercaloric diet enriched in saturated animal fats and cholesterol, a surprisingly higher effect than that 20 obtained with the corresponding mixtures of polycosanols in:

- . restoring membrane fluidity of ghosts and platelets;
- . improving antioxidant defenses of plasma, liver, brain and heart;
- . reducing excessive increase in body weight;
- . limiting excessive increase in plasma cholesterol and triglycerid levels.

25 Clinical trials were carried out on different groups of patients both healthy and suffering from one or more of the many aging-related dysmetabolic disorders (atherosclerosis; obesity and overweight; hypercholesterolemia and/or hypertriglyceridemia; hypertension; diabetes; cerebral-degenerative diseases such as

THIS PAGE BLANK

Alzheimer, Parkinson, senile dementia, loss of memory and the like; stress and/or depression; menopausal syndromes; prostate hypertrophy; osteoporosis; aging of the skin; panniculopathies (cellulite); alopecia). Patients were subjected to dietotherapeutic treatment with the mixtures reported in Example 1 or in Example 2. Doses and times
5 varied depending on the treated groups.

In all clinical trials, the beneficial, therapeutical effects obtainable with the administration of the mixtures reported in Example 1 or in Example 2 were always significantly high, in the prevention of aging biological symptoms (better membrane fluidity, improvement of antioxidant defenses, limitation of weight excesses) and in
10 the improvement of some of the tested clinical parameters; therefore said compositions may be usefully employed both in aging prevention and as coadjuvants and synergetic agents to improve the therapeutical action of drugs already normally in use in the treatment of the above cited diseases.

Furthermore, said beneficial aspects were always by far higher than the sum of
15 the effects obtainable by the administrations of the single active principles of the different mixtures.

Finally, these clinical trials in humans showed that the administration of a mixture of polycosanolic acids alone was surprisingly more effective in preventing aging biochemical symptoms (better membrane fluidity, improvement of antioxidant defenses, limitation of weight excesses, reduction of plasma cholesterol and triglycerides, etc.) than the administration of the mixture of the corresponding
20 polycosanols alone.

CLAIMS

1. Pharmaceutical, dietetic or alimentary compositions containing:
 - a) a lipidic mixture rich in polyunsaturated acids and vitamins, in combination with
5 at least two components selected from:
 - b) one or more terpenes selected from monoterpenes and/or sesquiterpenes;
 - c) 1-piperoylpiperidine in the pure form and/or extracts or purified fractions enriched in black pepper containing it;
 - d) one or more polycosanols and/or polycosanolic acids.
- 10 2. Compositions as claimed in claim 1, wherein monoterpenes are selected from d-limonene, β -caryophyllene, sabinene, borneol, carveol, carvone, eugenol, eugenol acetate, geraniol, menthol, myrtanol, pinene, β -pinene, thymol.
- 15 3. Compositions as claimed in claim 1, wherein sesquiterpenes are selected from β -ionone, rodinal, abscisic acid.
4. Compositions as claimed in claim 1, wherein polycosanols are selected from octacosanol, triacosanol, tetracosanol, hexacosanol.
5. Compositions as claimed in claim 1, wherein the polycosanolic acid is montanic acid.
- 20 6. Compositions as claimed in claim 1, wherein the lipidic mixture rich in unsaturated acids consists of an oil selected from fish, maize, soy-bean, sunflower, wheat germ, borage, red currant, evening primrose, olive oils.
7. Compositions as claimed in any one of the above claims containing components a), b) and c).
- 25 8. Compositions as claimed in any one of the above claims containing components a), b), c) and d).
9. Compositions as claimed in any one of the above claims containing components a), c) and d).
10. Compositions as claimed in any one of the above claims further containing

mineral salts, oligoelements, amino acids, phytosterols, bioflavones, plants extracts.

11. Compositions as claimed in claims 1-10 as agents capable of limiting the increase in body weight and membrane stiffness, having hypocholesterolemizing, hypoglycideridemizing and antioxidant activities.

5 12. Water-dispersible lipoprotein powders consisting of components a), b), c) and d) as defined in claim 1 and a water-soluble protein.

13. Lipoprotein powders as claimed in claim 12, wherein the water-soluble protein is selected from albumin, egg albumin, delipidized albumin, soy proteins, caseins, gelatins.

10 14. A process for the preparation of the lipoprotein powders of claims 12 and 13, which comprises subjecting to spray-drying a solution of components a), b) and/or c) and of the water-soluble protein.

15 15. Water-dispersible lipoprotein powders consisting of components a), b), c) and d) as defined in claim 1 and of a di - or polysaccharide.

16. Liposaccharide powders as claimed in claim 15, wherein the di- or polysaccharide is selected from saccharose, lactose, starches, cellulose, chitins, chitosans, pectins, insulin, cellulose fibers, cyclodextrins, honey or fractions thereof.

17. A process for the preparation of the liposaccharide powders of claims 15 and 16, which comprises subjecting to spray-drying an aqueous solution of components a), b), c) and d) and di- or polysaccharide.

18. The use of the lipoprotein powders of claims 12 and 13 and of the liposaccharide powders of claims 15 and 16 for the preparation of foodstuffs and galenic formulations.

19. Functional foodstuffs containing the water-dispersible powders of claims 12-13 and 15-16.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/11736

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7	A23L1/30 A23L1/221 A61K45/06	
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 7 A23L A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
EPO-Internal, WPI Data, PAJ, BIOSIS, FSTA		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Section Ch, Week 198629 Derwent Publications Ltd., London, GB; Class B05, AN 1986-186011 XP002190617 & JP 61 118318 A (PALA KASEI KOGYO KK), 5 June 1986 (1986-06-05) abstract</p> <p>----</p>	1
X	<p>DATABASE WPI Section Ch, Week 198819 Derwent Publications Ltd., London, GB; Class B05, AN 1988-129547 XP002190811 & JP 63 072654 A (SANMARU KAGAKU KK), 2 April 1988 (1988-04-02) abstract</p> <p>----</p>	1,2
A	<p>----</p> <p>-/-</p>	4,5
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
<p>* Special categories of cited documents :</p> <ul style="list-style-type: none"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed 		
<p>Date of the actual completion of the international search</p> <p>27 February 2002</p>		<p>Date of mailing of the international search report</p> <p>07/03/2002</p>
<p>Name and mailing address of the ISA</p> <p>European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016</p>		<p>Authorized officer</p> <p>Serbetsooglou, A</p>

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/11736

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 43036 A (HUNZA DI MARIA CARMELA MARAZZITA S.A.S.) 27 July 2000 (2000-07-27) claims ---	1, 10-19
A	WO 93 00015 A (KALAMAZOO HOLDINGS INC) 7 January 1993 (1993-01-07) claims; example 10 ---	1
A	GB 350 684 A (EDWIN MAYBURY) 18 June 1931 (1931-06-18) claims ---	1
A	EP 0 180 786 A (PISTOLESI ELVIRA) 14 May 1986 (1986-05-14) claims ---	1, 4, 10, 11
A	WO 99 22751 A (CHAMPON LOUIS S) 14 May 1999 (1999-05-14) claims 1-3 -----	1, 2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/11736

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
JP 61118318	A	05-06-1986	JP	1830686 C		15-03-1994
			JP	5042411 B		28-06-1993
JP 63072654	A	02-04-1988	NONE			
WO 0043036	A	27-07-2000	IT	MI990114 A1		24-07-2000
			IT	MI992471 A1		28-05-2001
			AU	2542500 A		07-08-2000
			WO	0043036 A2		27-07-2000
			EP	1143999 A2		17-10-2001
			US	6340669 B1		22-01-2002
WO 9300015	A	07-01-1993	US	5230836 A		27-07-1993
			AT	196979 T		15-11-2000
			CA	2071415 A1		21-12-1992
			DE	69231521 D1		23-11-2000
			DE	69231521 T2		08-03-2001
			DK	590029 T3		13-11-2000
			EP	0590029 A1		06-04-1994
			JP	3242404 B2		25-12-2001
			JP	6508748 T		06-10-1994
			WO	9300015 A1		07-01-1993
			US	5314686 A		24-05-1994
			US	5290481 A		01-03-1994
			US	5296249 A		22-03-1994
GB 350684	A	18-06-1931	NONE			
EP 0180786	A	14-05-1986	IT	1176916 B		18-08-1987
			AT	43242 T		15-06-1989
			DE	3570362 D1		29-06-1989
			EP	0180786 A1		14-05-1986
			JP	61112020 A		30-05-1986
			US	4780456 A		25-10-1988
WO 9922751	A	14-05-1999	US	6051233 A		18-04-2000
			AU	9683698 A		24-05-1999
			WO	9922751 A1		14-05-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.